Morgan and Mendel Genomics, Inc.
Blood tests using flow variant assay technology to detect hereditary cancer risks and DNA repair responses
- Sector
- Medtech
- Headquarters
- Wilmington, DE
- Total capital
- $6.5M
- Federal grants
- $6.5M
- 9 awards · 2017–2023
- Rank in peer group#104 of 538
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Robust Predictor of Colon Cancer Risk$1M
- Federal grantHealth and Human S · Phase II · Robust Predictor of Colon Cancer Risk$2M
- Federal grantDefense · Phase II · Novel, rapid and accurate blood tests for detecting hereditary cancer risk$695K
- Federal grantHealth and Human S · Phase II · Robust Predictor of Breast Cancer Risk$160K
- Federal grantHealth and Human S · Phase II · Robust Predictor of Breast Cancer Risk$1M
- Federal grantHealth and Human S · Phase II · Robust Predictor of Breast Cancer Risk$992K
- Federal grantHealth and Human S · Phase I · Robust Predictor of Colon Cancer Risk$300K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · Robust Predictor of Breast Cancer Risk$2K
- Federal grantHealth and Human S · Phase I · Robust Predictor of Breast Cancer Risk$302K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#104 · top 19%
- Linked publications#6 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 1- PendingRobust Genomic Predictor Of Breast And Lung Cancer MetastasisUSPTOApplication PCTUS2019016268
Recent research by its founders
- When Rare Is Common—Rethinking Pediatric Genetic Care20261 cites
- Data from Association of Intratumoral Microbiota with Prognosis in Head and Neck Squamous Cell Carcinoma20260 cites
- Supplementary Data 1 from Association of Intratumoral Microbiota with Prognosis in Head and Neck Squamous Cell Carcinoma20260 cites
Related companies, and why
- Brighton DevelopmentSimilar federal contract value in Medtech · null in contracts
- CytoTronics, Inc.Similar federal contract value in Medtech · null in contracts
- AMPA INC.Similar federal contract value in Medtech · null in contracts
- Pinnacle Technology, Inc.Similar federal contract value in Medtech · null in contracts
- NIGHTINGALE LABS CORPORATIONSimilar federal contract value in Medtech · null in contracts
- MANZANITA PHARMACEUTICALS, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .